Psychopharmacotherapy in Aged Patients

Štuhec, Matej; Stoppe, Gabriela

doi:10.1007/978-3-319-56015-1_269-1

Cited by 2 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Benzodiazepines were used by 54% and antipsychotics by 33% of all residents [22]. This means that polypharmacy is a frequent treatment approach, and careful psychopharmacological selection should be used because these patients are not covered by the existing treatment guidelines and RCTs [5,6,7 ▪ ].…”

Section: Polypharmacy In Elderly Patients With Schizophreniamentioning

confidence: 99%

“…Elderly patients with SCH on polypharmacy are less frequently studied because polypharmacy has not been reported and excluded [5,6,7 ▪ ]. These patients have been included in different studies covering nursing home, ambulatory, or hospital populations, although patients with SCH were mixed or separated from other patients [8,18,19].…”

Section: Polypharmacy In Elderly Patients With Schizophreniamentioning

confidence: 99%

“…SCH is being treated with pharmacotherapy, where antipsychotics are a key medication group [5,6]. Elderly patients with SCH are frequently treated with several different medications (antipsychotics and comedications), including polypharmacy (five or more medications at the same time) [7 ▪ ]. Polypharmacy is especially prevalent in patients with mental disorders, where antipsychotics are often involved in significant drug–drug interactions (DDIs), potential inappropriate medications (PIMs) and irrational polypharmacy (e.g., no clear indication) [8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Antipsychotic treatment in elderly patients on polypharmacy with schizophrenia

Štuhec¹

2022

Current Opinion in Psychiatry

Self Cite

View full text Add to dashboard Cite

Purpose of reviewElderly patients with schizophrenia (SCH) are treated with antipsychotics and are often on different comedications, including polypharmacy (five or more medications). Evidence-based guidelines and randomized controlled trials do not include patients on polypharmacy, something that represents a 'gap' between evidence-based recommendations and clinical prescribing patterns. In this context, narrative reviews are needed to help clinicians in daily practice. Recent findingsAntipsychotic treatment efficacies in meta-analyses are similar in the elderly with SCH compared with the general population (medium effect size). Long-term cohort studies show that antipsychotic treatment reduces overall mortality, hospitalizations, and cardiovascular death. These studies are limited because polypharmacy was not studied. The prevalence of antipsychotic use as potentially inappropriate medications was very high in nursing homes (25%). The prevalence of antipsychotic polypharmacy was 40%. Different strategies to manage these problems are available, including collaboration with clinical pharmacists, leading to reduced polypharmacy and better adherence to treatment guidelines. SummaryElderly patients with SCH on polypharmacy are less frequently studied, although they represent many patients with SCH. Different potentially inappropriate medication lists and collaboration with clinical pharmacists represent effective strategies for medication optimization. More studies are needed on this topic (e.g., prospective nonrandomized studies).

show abstract

Section: Polypharmacy In Elderly Patients With Schizophreniamentioning

confidence: 99%

Section: Polypharmacy In Elderly Patients With Schizophreniamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antipsychotic treatment in elderly patients on polypharmacy with schizophrenia

Štuhec¹

2022

Current Opinion in Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

Depressive Spectrum Disorders in Neurological Practice: Is There a Place Under the Sun, or Who Should Treat Patients?

Antsyborov

Dubatova

2021

ISci

View full text Add to dashboard Cite

In the cases of majority of neurological diseases the symptoms of depression have significant influence on the worsening of the quality of patient’s life, regardless of the severity of the neurological disorders. In the most of neurodegenerative diseases the symptoms of depression often precede the appearance of neurological symptoms. Within recent years, numerous studies have been published demonstrating that disorders of depressive spectrum can be considered as a predictor of some types of dementia. Existing data regarding the methods of therapeutic intervention for depression in the clinical practice are rather scarce, scattered and often based on the «personal experience» of neurologists and psychiatrists. In some patients the diagnostics of depression in the context of neurological disorders can be difficult due to the difficulties in the establishing the contact with the patient as well as cognitive deviations related to neurological disorders. In order to facilitate this task, the effective screening diagnostic methods have been developed for the diagnosis of depression in the context of neurological diseases. The results of clinical studies performed within recent years confirm the important role of the neurologist for the evaluation and the treatment of the symptoms of depression, both at the initial stage and at the stage of remission. The purpose of the current review is to systematize the accumulated data on the disorders of depressive spectrum in the context of neurological practice, as well as to demonstrate the role of neurologist in the process of diagnosis and treatment of the symptoms of depression in neurological diseases.

show abstract

Psychopharmacotherapy in Aged Patients

Cited by 2 publications

References 23 publications

Antipsychotic treatment in elderly patients on polypharmacy with schizophrenia

Antipsychotic treatment in elderly patients on polypharmacy with schizophrenia

Depressive Spectrum Disorders in Neurological Practice: Is There a Place Under the Sun, or Who Should Treat Patients?

Contact Info

Product

Resources

About